Journal of Literature Pharmacy Sciences

Lipid Temelli Taşıyıcı Sistemler-II: Katı Kendiliğinden Emülsifiye İlaç Taşıyıcı Sistem Formülasyonlarına Bakış: Geleneksel Derleme
Lipid-Based Delivery Systems-II: Overwiev of Solid Self-Emulsifying Drug Delivery System Formulations: Traditional Review
Duygu YILMAZ USTAa , Zeynep Şafak TEKSİNa
aGazi Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji AD, Biyofarmasötik ve Farmakokinetik BD, Ankara, Türkiye
J Lit Pharm Sci. 2025;14(1):17-25
doi: 10.5336/pharmsci.2024-104969
Article Language: TR
Full Text
ÖZET
 Kendiliğinden emülsifiye ilaç taşıyıcı sistemler [selfemulsifying drug delivery systems SEDDS)], lipid temelli sistemler olup çözünürlük problemi olan etkin maddelerin oral yoldan verilişinde son yıllarda başarı ile uygulanmaktadır. Bu lipid temelli ilaç taşıyıcı sistemler birey içi ve bireyler arası değişkenliği azaltması, gıda etkisini azaltması ve hepatik ilk geçiş etkisine uğramadan lenfatik yol boyunca emilmesi açısından büyük avantaj sağlamaktadır. Bununla birlikte, formülasyonu meydana getiren bileşenlerden sürfaktan miktarının yüksek olması nedeniyle mide bağırsak kanalında irritasyona neden olması, stabiliteleri, dozlama için en uygun seçenek olan yumuşak jelatin teknolojisinin pahalı olması, yağlı bileşenlerin kapsül duvarına taşınması, kapsül duvarından sızması ve zayıf taşınabilirlik gibi problemlere de sahiptir. Bahsedilen problemlerin aşılabilmesi için SEDDS'nin katı SEDDS şekline getirilmesi uygun bir formülasyon stratejisidir. Bu amaçla uygulanan sıvı ve yarı katı formülasyonların kapsüllere dolumu, püskürterek dondurma/kurutma, liyofilizasyon ve katı taşıyıcılara adsorpsiyon gibi teknikler bulunmaktadır. Bu derleme makalesinde, kendiliğinden emülsifiye ilaç taşıyıcı sistem formülasyonlarında karşılaşılan problemlerin üstesinden gelebilmek için SEDDS'nin katı kendiliğinden emülsifiye ilaç taşıyıcı sistem dozaj şekillerine dönüştürülmesine, bu amaçla kullanılan yardımcı maddelere ve özelliklerine, katılaştırma işlemi için kullanılan tekniklere, katı kendiliğinden emülsifiye ilaç taşıyıcı sistemin avantajlarına ve dezavantajlarına, kalite denetimlerine, farklı teknikler ile hazırlanan katı kendiliğinden emülsifiye ilaç taşıyıcı sistem çalışmalarına, literatür ve patent örneklerine yer verilmiştir.

Anahtar Kelimeler: Lipid temelli sistemler; katı kendiliğinden emülsifiye sistemler; katılaştırma teknikleri; çözünürlük artırma
ABSTRACT
 Self-emulsifying drug delivery systems (SEDDS) are lipid-based systems and have been successfully applied in recent years for the oral administration of active substances with solubility problems. These lipid-based drug carrier systems provide significant advantages in reducing intra- and inter-individual variability, reducing the effect of food, and being absorbed through the lymphatic pathway without undergoing hepatic first-pass effects. However, it also has problems such as irritating the gastrointestinal tract due to the high amount of surfactant, one of the components that make up the formulation, their stability, the expensiveness of soft gelatin technology, which is the most suitable option for dosing, transportation of oily components to the capsule wall, leakage from the capsule wall, and poor portability. In order to overcome the mentioned problems, turning SEDDS into solid SEDDS is a suitable formulation strategy. Techniques applied include filling liquid and semi-solid formulations into capsules, spray freezing/drying, lyophilization, and adsorption to solid carriers. In this review article, in order to overcome the problems encountered in SEDDS formulations, the conversion of SEDDS into solid SEDDS dosage forms, the excipients used for this purpose and their properties, the techniques used for the solidification process, the solid SEDDS. For these systems also are included advantages and disadvantages, quality controls, solid SEDDS studies prepared with different techniques, literature, and patent examples.

Keywords: Lipid-based systems; solid self-emulsifying systems; solidification techniques; enhance solubility
REFERENCES:
  1. Dey S, Nagababu BH. Applications of food color and bio-preservatives in the food and its effect on the human health. Food Chem Adv. 2022;1:100019. [Crossref] 
  2. World Health Organization [Internet]. Food Additives. ©2024 WHO [Cited: March 28, 2024]. Available from: [Link] 
  3. Durazzo A, Carocho M, Heleno S, Barros L, Souto EB, Santini A, et al. Food Dyes and Health: Literature Quantitative Research Analysis. Measurement: Food. 2022;7:100050. [Crossref] 
  4. Ribeiro JS. Food Additives: Natural Food Dyes. Ann Nutr Food Sci. 2019;3(1):1040. [Link] 
  5. Amchova P, Kotolova H, Ruda-Kucerova J. Health safety issues of synthetic food colorants. Regul Toxicol Pharmacol. 2015;73(3):914-22. [Crossref]  [PubMed] 
  6. Mortensen A. Carotenoids and other pigments as natural colorants. Pure and Applied Chemistry. 2006;78(8):1477-91. [Crossref] 
  7. Ramesh M, Muthuraman A. Flavoring and coloring agents: Health risks and potential problems. In: Grumezescu AM, Holban AM, eds. Natural and artificial flavoring agents and food dyes. Handbook of food bioengineering. Volume 7. London: Academic Press; 2018. p.1-28. [Crossref]  [PMC] 
  8. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 164825, Tartrazine; [Cited: April 18, 2024]. Available from: [Link] 
  9. Floriano JM, da Rosa E, do Amaral QDF, Zuravski L, Chaves PEE, Machado MM, et al. Is tartrazine really safe? In silico and ex vivo toxicological studies in human leukocytes: a question of dose. Toxicol Res (Camb). 2018;7(6):1128-34. [Crossref]  [PubMed]  [PMC] 
  10. Dos Santos JR, de Sousa Soares L, Soares BM, de Gomes Farias M, de Oliveira VA, de Sousa NAB, et al. Cytotoxic and mutagenic effects of the food additive tartrazine on eukaryotic cells. BMC Pharmacol Toxicol. 2022;23(1):95. [Crossref]  [PubMed]  [PMC] 
  11. Elhkim MO, Héraud F, Bemrah N, Gauchard F, Lorino T, Lambré C, et al. New considerations regarding the risk assessment on tartrazine an update toxicological assessment, intolerance reactions and maximum theoretical daily intake in France. Regul Toxicol Pharmacol. 2007;47(3):308-16. [Crossref]  [PubMed] 
  12. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS); Scientific Opinion on the re-evaluation Tartrazine (E 102). EFSA Journal. 2009;7(11):1331. [Crossref] 
  13. Food and Agriculture Organization of the United Nations [Internet]. 82nd Joint FAO/WHO Expert Committee on Food Additives (JECFA) meeting-Food additives. Summary and conclusions. June 7-16, 2016. Available from: [Link] 
  14. Ye X, Du Y, Lu D, Wang C. Fabrication of β-cyclodextrin-coated poly (diallyldimethylammonium chloride)-functionalized graphene composite film modified glassy carbon-rotating disk electrode and its application for simultaneous electrochemical determination colorants of sunset yellow and tartrazine. Anal Chim Acta. 2013;779:22-34. [Crossref]  [PubMed] 
  15. Amin KA, Abdel Hameid H 2nd, Abd Elsttar AH. Effect of food azo dyes tartrazine and carmoisine on biochemical parameters related to renal, hepatic function and oxidative stress biomarkers in young male rats. Food Chem Toxicol. 2010;48(10):2994-9. [Crossref]  [PubMed] 
  16. Abd-Elhakim YM, Moustafa GG, Hashem MM, Ali HA, Abo-El-Sooud K, El-Metwally AE. Influence of the long-term exposure to tartrazine and chlorophyll on the fibrogenic signalling pathway in liver and kidney of rats: the expression patterns of collagen 1-α, TGFβ-1, fibronectin, and caspase-3 genes. Environ Sci Pollut Res Int. 2019;26(12):12368-78. [Crossref]  [PubMed] 
  17. Tanaka T. Reproductive and neurobehavioural toxicity study of tartrazine administered to mice in the diet. Food Chem Toxicol. 2006;44(2):179-87. [Crossref]  [PubMed] 
  18. Diacu E, Ene CP. Simultaneous determination of tartrazine and sunset yellow in soft drinks by liquid chromatography. Revista de Chimie. 2009;60(8):745-9. [Link] 
  19. Poul M, Jarry G, Elhkim MO, Poul JM. Lack of genotoxic effect of food dyes amaranth, sunset yellow and tartrazine and their metabolites in the gut micronucleus assay in mice. Food Chem Toxicol. 2009;47(2):443-8. [Crossref]  [PubMed] 
  20. Mpountoukas P, Pantazaki A, Kostareli E, Christodoulou P, Kareli D, Poliliou S, et al. Cytogenetic evaluation and DNA interaction studies of the food colorants amaranth, erythrosine and tartrazine. Food Chem Toxicol. 2010;48(10):2934-44. [Crossref]  [PubMed] 
  21. Axon A, May FE, Gaughan LE, Williams FM, Blain PG, Wright MC. Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology. 2012;298(1-3):40-51. [Crossref]  [PubMed] 
  22. Kashanian S, Zeidali SH. DNA binding studies of tartrazine food additive. DNA Cell Biol. 2011;30(7):499-505. [Crossref]  [PubMed] 
  23. Matsuo H, Yokooji T, Morita H, Ooi M, Urata K, Ishii K, et al. Aspirin augments IgE-mediated histamine release from human peripheral basophils via Syk kinase activation. Allergol Int. 2013;62(4):503-11. [Crossref]  [PubMed] 
  24. Freitas AS. Tartrazina: uma revisão das propriedades e análises de quantificação [Tartrazine: a review of properties and quantification analyzes]. Acta Tecnológica. 2012;7(2):65-72. [Crossref] 
  25. Himri I, Bellahcen S, Souna F, Belmakki F, Aziz M, Bnouham M, et al. A 90-day oral toxicity study of tartrazine, a synthetic food dye, in wistar rats. Int J Pharm Pharm Sci. 2011;3(3):159-69. [Link] 
  26. Josephy PD, Allen-Vercoe E. Reductive metabolism of azo dyes and drugs: Toxicological implications. Food Chem Toxicol. 2023;178:113932. [Crossref]  [PubMed] 
  27. Tawfek NS, Amin HM, Abdalla AA, Fargali SHM. Adverse effects of some food additives in adult male albino rats. Current Science International. 2015;4(4):525-37. [Link] 
  28. Atlı Şekeroğlu Z, Güneş B, Kontaş Yedier S, Şekeroğlu V, Aydın B. Effects of tartrazine on proliferation and genetic damage in human lymphocytes. Toxicol Mech Methods. 2017;27(5):370-5. [Crossref]  [PubMed] 
  29. Soares BM, Araújo TM, Ramos JA, Pinto LC, Khayat BM, De Oliveira Bahia M, et al. Effects on DNA repair in human lymphocytes exposed to the food dye tartrazine yellow. Anticancer Res. 2015;35(3):1465-74. [PubMed] 
  30. Haveric A, Inajetovic D, Veresi A, Hadzic M, Haveric S. In vitro analysis of tartrazine genotoxicity and cytotoxicity. Genetics & Applications. 2017;1(1):37-43. [Crossref] 
  31. Khayyat L, Essawy A, Sorour J, Soffar A. Tartrazine induces structural and functional aberrations and genotoxic effects in vivo. PeerJ. 2017;5:e3041. [Crossref]  [PubMed]  [PMC] 
  32. Maekawa A, Matsuoka C, Onodera H, Tanigawa H, Furuta K, Kanno J, et al. Lack of carcinogenicity of tartrazine (FD & C Yellow No. 5) in the F344 rat. Food Chem Toxicol. 1987;25(12):891-6. [Crossref]  [PubMed] 
  33. Borzelleca JF, Hallagan JB. A chronic toxicity/carcinogenicity study of FD & C Yellow No. 5 (tartrazine) in mice. Food Chem Toxicol. 1988;26(3):189-94. [Crossref]  [PubMed] 
  34. Moutinho IL, Bertges LC, Assis RV. Prolonged use of the food dye tartrazine (FD&C yellow no 5) and its effects on the gastric mucosa of Wistar rats. Braz J Biol. 2007;67(1):141-5. [Crossref]  [PubMed] 
  35. Demirkol O, Zhang X, Ercal N. Oxidative effects of Tartrazine (CAS No. 1934-21-0) and New Coccin (CAS No. 2611-82-7) azo dyes on CHO cells. J. Verbr. Lebensm. 2012;7:229-36. [Crossref] 
  36. Mahmoud ES, Abd Elwahab AH, Yousuf AF. The alleviative effect of thymoquinone on cerebellar injury induced by food azo dye in rats. Al-Azhar Medical Journal. 2018;47(2):403-22. [Crossref] 
  37. Essawy AE, Mohamed AI, Ali RG, Ali AM, Abdou HM. Analysis of melatonin-modulating effects against tartrazine-ınduced neurotoxicity in male rats: biochemical, pathological and ımmunohistochemical markers. Neurochem Res. 2023;48(1):131-41. [Crossref]  [PubMed]  [PMC] 
  38. El-Sakhawy MA, Mohamed DW, Ahmed YH. Histological and immunohistochemical evaluation of the effect of tartrazine on the cerebellum, submandibular glands, and kidneys of adult male albino rats. Environ Sci Pollut Res Int. 2019;26(10):9574-84. [Crossref]  [PubMed] 
  39. Gao Y, Li C, Shen J, Yin H, An X, Jin H. Effect of food azo dye tartrazine on learning and memory functions in mice and rats, and the possible mechanisms involved. J Food Sci. 2011;76(6):T125-9. [Crossref]  [PubMed] 
  40. Kamel MM, El-lethey HS. The potential health hazard of tartrazine and levels of hyperactivity, anxiety-like symptoms, depression and anti-social behaviour in rats. J. Am. Sci. 2011;7(6):1211-8. [Link] 
  41. Feingold BF. Hyperkinesis and learning disabilities linked to artificial food flavors and colors. Am J Nurs. 1975;75(5):797-803. [Crossref]  [PubMed] 
  42. Levy F, Dumbrell S, Hobbes G, Ryan M, Wilton N, Woodhill JM. Hyperkinesis and diet: a double-blind crossover trial with a tartrazine challenge. Med J Aust. 1978;1(2):61-4. [Crossref]  [PubMed] 
  43. Sharma KA, Choudhary PB. Tartrazine synthesis, applications and issues: A case study. Journal of Critical Reviews. 2020;7(3):2437-41.
  44. Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. J Dev Behav Pediatr. 2004;25(6):423-34. [Crossref]  [PubMed] 
  45. McCann D, Barrett A, Cooper A, Crumpler D, Dalen L, Grimshaw K, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet. 2007;370(9598):1560-7. Erratum in: Lancet. 2007;370(9598): 1542. [Crossref]  [PubMed] 
  46. Oyewole OI, Oladele JO. Assessment of cardiac and renal functions in Wistar albino rats administered carmoisine and tartrazine. Advances in Biochemistry. 2016;4(3):21-5. [Crossref] 
  47. Megahed R, Barghash S, Hasan R. Sub-chronic toxic effects of tartrazine on the heart and brain of adult male albino rats and the protective effect of vitamin E. Journal of Recent Advances in Medicine. 2022;3(1):19-30. [Crossref] 
  48. Abd El-Hakam FE, Farrag IM. Tartrazine: Potential hepatorenal and cardiovascular toxicity and the possible protective effect of vitamin E in Wistar rats. Journal of Recent Advances in Medicine. 2022;3(2):96-107. [Crossref] 
  49. El Rabey HA, Al-Seeni MN, Al-Sieni AI, Al-Hamed AM, Zamzami MA, Almutairi FM. Honey attenuates the toxic effects of the low dose of tartrazine in male rats. J Food Biochem. 2019;43(4):e12780. [Crossref]  [PubMed] 
  50. El-Desoky GE, Abdel-Ghaffar A, Al-Othman ZA, Habila MA, Al-Sheikh YA, Ghneim HK, et al. Curcumin protects against tartrazine-mediated oxidative stress and hepatotoxicity in male rats. Eur Rev Med Pharmacol Sci. 2017;21(3):635-45. [PubMed] 
  51. Altınoz E, Erdemli ME, Gul M, Erdemli Z, Gul S, Turkoz Y. Prevention of toxic effects of orally administered tartrazine by crocin in Wistar rats. Toxicological & Environmental Chemistry. 2021;103(2):184-98. [Crossref] 
  52. Ameur FZ, Mehedi N, Kheroua O, Saïdi D, Salido GM, Gonzalez A. Sulfanilic acid increases intracellular free-calcium concentration, induces reactive oxygen species production and impairs trypsin secretion in pancreatic AR42J cells. Food Chem Toxicol. 2018;120:71-80. [Crossref]  [PubMed] 
  53. El Golli N, Bini-Dhouib I, Jrad A, BoudaliI I, Nasri B, Belhadjhmida N, et al. Toxicity induced after subchronic administration of the synthetic food dye tartrazine in adult rats,role of oxidative stress. Recent Adv Biol Med. 2016;2:20-8. [Crossref] 
  54. Erdemli Z, Altinoz E, Erdemli ME, Gul M, Bag HG, Gul S. Ameliorative effects of crocin on tartrazine dye-induced pancreatic adverse effects: a biochemical and histological study. Environ Sci Pollut Res Int. 2021;28(2):2209-18. [Crossref]  [PubMed] 
  55. Mehedi N, Ainad-Tabet S, Mokrane N, Addou S, Zaoui C, Kheroua O, et al. Reproductive toxicology of tartrazine (FD and C yellow no. 5) in swiss albino mice. American Journal of Pharmacology and Toxicology. 2009;4(4):130-5. [Crossref] 
  56. Wopara I, Modo EU, Mobisson SK, Olusegun GA, Umoren EB, Orji BO, et al. Synthetic Food dyes cause testicular damage via up-regulation of pro-inflammatory cytokines and down-regulation of FSH-R and TESK-1 gene expression. JBRA Assist Reprod. 2021;25(3):341-8. [Crossref]  [PubMed]  [PMC] 
  57. Mindang ELN, Awounfack CF, Ndinteh DT, Krause RWM, Njamen D. Effects of tartrazine on some sexual maturation parameters in ımmature female wistar rats. Int J Environ Res Public Health. 2022;19(16):10410. [Crossref]  [PubMed]  [PMC] 
  58. Nasri A, Pohjanvirta R. In vitro estrogenic, cytotoxic, and genotoxic profiles of the xenoestrogens 8-prenylnaringenine, genistein and tartrazine. Environ Sci Pollut Res Int. 2021;28(22):27988-97. [Crossref]  [PubMed]  [PMC] 
  59. Shakoor S, Ismail A, Zia-Ur-Rahman, Sabran MR, Bekhit AEDA, Roohinejad S. Impact of tartrazine and curcumin on mineral status, and thyroid and reproductive hormones disruption in vivo. Int Food Res J. 2022;29(1):186-99. [Crossref] 
  60. Datta P, Lundin-Schiller S. Estrogenicity of the synthetic food colorants tartrazine, erythrosin B, and sudan I in an estrogenresponsive human breast cancer cell line. Journal of the Tennessee Academy of Science. 2008;83:45-51. [Link] 
  61. Hashem MM, Abd-Elhakim YM, Abo-El-Sooud K, Eleiwa MME. Embryotoxic and teratogenic effects of tartrazine in rats. Toxicol Res. 2019;35(1):75-81. [Crossref]  [PubMed]  [PMC] 
  62. Öztürk O, Dikici Y, Gür Ö, Ocak M, Doğanyiğit Z, Okan A, et al. Evaluation of the effect of tartrazine on the offspring rats in an in vivo experimental model. Food Sci Nutr. 2024;12(11):9162-74. [Crossref]  [PubMed]  [PMC] 
  63. Albasher G, Maashi N, Alfarraj S, Almeer R, Albrahim T, Alotibi F, et al. Perinatal Exposure to Tartrazine Triggers Oxidative Stress and Neurobehavioral Alterations in Mice Offspring. Antioxidants (Basel). 2020;9(1):53. [Crossref]  [PubMed]  [PMC] 
  64. Neuman I, Elian R, Nahum H, Shaked P, Creter D. The danger of "yellow dyes" (tartrazine) to allergic subjects. Clin Allergy. 1978;8(1):65-8. [Crossref]  [PubMed] 
  65. Young E, Patel S, Stoneham M, Rona R, Wilkinson JD. The prevalence of reaction to food additives in a survey population. J R Coll Physicians Lond. 1987;21(4):241-7. [Crossref]  [PubMed]  [PMC] 
  66. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Suspected tartrazine-induced acute urticaria/angioedema is only rarely reproducible by oral rechallenge. Clin Exp Allergy. 2003;33(12):1725-9. [Crossref]  [PubMed] 
  67. Lockey SD. Allergic reactions due to F D and C Yellow No. 5, tartrazine, an aniline dye used as a coloring and identifying agent in various steroids. Ann Allergy. 1959;17:719-21. [PubMed] 
  68. Ardern KD, Ram FS. Tartrazine exclusion for allergic asthma. Cochrane Database Syst Rev. 2001;2001(4):CD000460. [PubMed]  [PMC] 
  69. Weber RW, Hoffman M, Raine DA Jr, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol. 1979;64(1):32-7. [Crossref]  [PubMed] 
  70. Barnes PJ. Drug-induced Asthma. In: Barnes PJ, Rodger IW, Thomson NC, eds. Asthma: Basic mechanisms and clinical management. 3rd ed. London:Academic Press; 1998. p.487-506. [Crossref] 
  71. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68(5):975-83. [Crossref]  [PubMed] 
  72. Ceserani R, Colombo M, Robuschi M, Bianco S. Tartrazine and prostaglandin-system. Prostaglandins Med. 1978;1(6):499-505. [Crossref]  [PubMed] 
  73. Gerber JG, Payne NA, Oelz O, Nies AS, Oates JA. Tartrazine and the prostaglandin system. J Allergy Clin Immunol. 1979;63(4):289-94. [Crossref]  [PubMed] 
  74. Bhatia MS. Allergy to tartrazine in psychotropic drugs. J Clin Psychiatry. 2000;61(7):473-6. [Crossref]  [PubMed] 
  75. Desmond RE, Trautlein JJ. Tartrazine (FD & C yellow #5) anaphylaxis: a case report. Ann Allergy. 1981;46(2):81-2. [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 154 - 153
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 197
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 197
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com